环孢素A和司坦唑醇联合咖啡酸片方案治疗慢性再生障碍性贫血的临床疗效研究  

Cinlincal Observation of Caffeic Acid tablet in Treatment of Alpastic Anemia

作　　者：刘冯[1] 肖丁华[1] 莫东华[1] 文飞球 

机构地区：[1]桂林医学院附属医院血液科,广西桂林市541001 [2]暨南大学第二临床医学院深圳市人民医院儿科

出　　处：《临床合理用药杂志》2011年第01X期13-15,共3页Chinese Journal of Clinical Rational Drug Use

基　　金：广西壮族自治区卫生厅科研项目(Z2008281)

摘　　要：目的探讨环孢素A、司坦唑醇联合咖啡酸片治疗初治慢性再生障碍性贫血(CAA)的疗效及发挥疗效的机制。方法将92例CAA患者随机分成两组,实验组予以环孢素A、司坦唑醇联合咖啡酸片治疗方案;对照组予以环孢素A、司坦唑醇治疗方案。结果实验组治疗后,无效2例,稍缓解25例,部分缓解20例,完全缓解2例;对照组治疗后,无效8例,稍缓解18例,部分缓解16例,完全缓解1例,两组疗效间差异有统计学意义(χ2=3.879,P<0.05)。;两组患者的血清粒细胞集落刺激因子水平和血清血小板生成素水平在治疗前无显著性差异,治疗后实验组患者的血清粒细胞集落刺激因子水平和血清血小板生成素水平明显低于对照组(P<0.05);两组患者的骨髓粒细胞系所占比例和巨核细胞数在治疗前无显著性差异,治疗后实验组患者的骨髓粒细胞系所占比例和巨核细胞计数明显高于对照组(P<0.05)。结论咖啡酸片对治疗慢性再生障碍性贫血有很好的疗效,有临床应用价值。Objective To assess the effects and humoral and cellular mechanismsof cyclosporin A、stanozolol and caffeic acid tablet on chronic alpastic anemia.Methods 92 CAA patients were radomly divided into experimental group and control group.treatment group was given cyclosporinA、stanozolol and oral caffeic acid tablets;control group was only given cyclosporinA and stanozolol.Results The effective of rate was 95.9% in experimental group and 81.3% in control group,with statistical difference（P〈0.05）between the two groups.There is no significant difference serum granulocyte colony-stimulating factor and serum thrombopoietin in CAA patient between the experimental group and control group before treatment,and serum granulocyte colony-stimulating factor and serum thrombopoietin were decline considerably in the experimental group （P〈0.05） after treatment.There is no significant difference bone marrow granulocyte ratio and megakaryocyte count in CAA patient between the experimental group and control group before treatment,and bone marrow granulocyte ratio and megakaryocyte count were elevated considerably in the experimental group （P〈0.05 ） after treatment.Conclusion The caffeic acid tablet have efficacy in treatment of chronic alpastic anemia and is worthy of popularization.

关 键 词：咖啡酸片 贫血 再生障碍性 血小板减少 白细胞减少 

分 类 号：R556.5[医药卫生—血液循环系统疾病]